Driving Translational Imaging to a Drug Industry Standard: Case Studies in Glioblastoma and Other Clinically Predictive Cancer Models

Medical imaging technologies can facilitate drug discovery, efficacy evaluation, and translation into the clinic. Now a maturing platform, molecular imaging is the catalyst for a new standard of how drug candidates are evaluated and advanced into trials. By providing clinically translatable biomarkers as an accompaniment to standard measures of response, imaging leverages and amplifies the […]

Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging

With the ability to provide non-invasive, three dimensional, and quantitative data; PET, SPECT, and fluorescence imaging (FMT) enable translational imaging of biodistribution, molecular and cellular targeting, competitive binding and PK/PD. These imaging applications have become critical assays for biologics characterization for discovery screening, lead candidate selection, optimization and safety. The use of imaging-based biodistribution applications […]

Advances in Inflammation Models and Associated Drug Evaluation: Improved Assessment Using Imaging Biomarkers

Molecular Imaging’s Patrick McConville, Ph.D and James Mobley Ph.D., Founder and CSO, Sunapten Therapeutics, Inc. discussed how advances in the understanding of the pathophysiology of human inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease have been aided by the development of clinically translatable animal models, and increasingly sophisticated means of assessing drug efficacy in […]